According to one expert, the evidence is shifting towards a causal link between rare blood clots and the Oxford / AstraZeneca Covid-19 vaccine.
The Medicines and Health Products Regulatory Authority (MHRA) said it had identified 30 rare blood clot events from 18.1 million doses of the sting administered up to and including March 24th.
Among the 30 cases, there were seven deaths.
However, the Medicines and Healthcareeregulator says the vaccine’s benefits outweigh the risks and urged the public to continue to sign up for the sting.
The benefits of the AstraZeneca Covid-19 vaccine in preventing Covid-19 infection and its complications continue to outweigh any risks.
The regulator has not released any information about the seven deceased, such as age or health status.
The 30 cases include 22 reports of cerebral venous sinus thrombosis (CVST) and eight other low platelet thrombosis events.
CVST clots prevent blood from properly draining out of the brain.
Professor Paul Hunter, a medical microbiologist at the University of East Anglia, told BBC Radio 4 Today: “It is not uncommon for clusters of rare events to occur purely by chance.
“But if you find this cluster in one population and then it appears in another – as it used to be in German and now in English – then I think the probability that it is a random association is very, very small .
“Clearly more work needs to be done, but I think the evidence is now shifting more towards a causal link.”
However, he said the risks of taking the AstraZeneca vaccine still far outweigh the risks of not getting the sting.
“The chances of dying if you don’t have the vaccine are many times greater than the chances of dying of CVT (cerebral vein thrombosis) after receiving the AstraZeneca vaccine, even if I suspect the link turns out to be exists is causal, ”he said.
Germany is suspending the use of the AstraZeneca vaccine for people under 60 for fear of being linked to rare blood clots.
On Friday, the Dutch government also announced it would temporarily stop AstraZeneca puffs for anyone under 60 after receiving five reports of blood clots with low platelet counts following vaccinations.
However, the head of the European Medicines Agency (EMA) said there was “no evidence” to support a restriction on the use of the AstraZeneca vaccine in a population.
The agency said a causal link between unusual blood clots in people who received the vaccine was “not proven but possible,” adding that the vaccine’s benefits outweigh the risks of side effects.
This view is borne out by the World Health Organization (WHO), which has urged countries to keep using the push.
Dr. June Raine, Managing Director of MHRA said, “The benefits of the Covid-19 vaccine AstraZeneca in preventing and complications from Covid-19 continue to outweigh any risks and the public should continue to receive their vaccine when prompted .
“As published in our most recent weekly yellow card summary for Covid-19 vaccines, as of March 24th, we had received 22 reports of CVST and eight reports of other low platelet thrombosis events totaling 18.1 million administered up to that date Doses of the Covid-19 vaccine AstraZeneca.
“There were no reports for the Pfizer / BioNTech vaccine. Our thorough examination of these reports is ongoing.
“We ask healthcare professionals to report any cases they suspect may be related to the Covid-19 vaccination through the coronavirus yellow card website.”